IP Library Granted Patent US 8,784,840
Granted Patent B2
US 8,784,840 · App. 12/617,653 · Granted Jul 22, 2014

Method for screening modulators of apoptosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,840
App. No.
12/617,653
Granted
Jul 22, 2014
Kind
B2
Abstract

The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

Claims (13)

1. A method of treating a mammal from ionizing radiation induced apoptosis tissue damage comprising administering to a mammal in need thereof a composition comprising flagellin.

2. The method of claim 1 wherein the composition is administered in combination with a radioprotectant.

3. The method of claim 2 wherein the radioprotectant is an antioxidant.

4. The method of claim 3 wherein the antioxidant is selected from the group consisting of amifostine and vitamin E.

5. The method of claim 2 wherein the radioprotectant is a cytokine.

6. The method of claim 5 , wherein the cytokine is stem cell factor.

7. The method of claim 1 wherein the radiation exposure is radiation therapy for treating cancer.

8. The method of claim 1 wherein the composition is administered prior to, together with, or after the treatment.

9. The method of claim 1 , wherein the composition is administered in combination with a growth factor.

10. The method of claim 9 , wherein the growth factor is keratinocyte growth factor.

11. The method of claim 1 , wherein the composition is administered in combination with a steroid.

12. The method of claim 11 , wherein the steroid is 5-adrostenediol.

13. The method of claim 1 , wherein the composition is administered in combination with ammonium trichloro(dioxoethylene-0-0′)tellurate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2013
From: GUDKOV, ANDREI V.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 030500/0612 →